


## Promestriene

<b>Cat. No.:</b>	HY-108293		
<b>CAS No.:</b>	39219-28-8		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>32</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	328.49		
<b>Target:</b>	Estrogen Receptor/ERR		
<b>Pathway:</b>	Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 20 mg/mL (60.88 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	3.0442 mL	15.2212 mL	30.4423 mL
		5 mM	0.6088 mL	3.0442 mL	6.0885 mL
10 mM		0.3044 mL	1.5221 mL	3.0442 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2 mg/mL (6.09 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (6.09 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Promestriene is a synthetic diethyl-ether of estradiol and a locally effective estrogen. Promestriene has an efficient action on vaginal atrophy while it is minimally absorbed <sup>[1][2]</sup> .
<b>In Vitro</b>	Promestriene is an analogue of oestradiol which is minimally absorbed and devoid of systemic effects when administered intravaginally, either as gynecological cream or capsules <sup>[2]</sup> . Topical Promestriene is minimally absorbed with chronic use and has been reported to significantly improve the symptoms of vaginal atrophy <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

- [1]. Isabel Santos, et al. Urogenital Disorders Associated With Oestrogen Deficiency: The Role of Promestriene as Topical Oestrogen Therapy. *Gynecol Endocrinol*. 2010 Sep;26(9):644-51.
- [2]. Lino Del Pup, et al. Promestriene, a Specific Topic Estrogen. Review of 40 Years of Vaginal Atrophy Treatment: Is It Safe Even in Cancer Patients. *Anticancer Drugs*. 2013 Nov;24(10):989-98.
- [3]. AJO Almodovar, et al. Abstract P5-05-07: Promestriene effects on estrogen-sensitive breast cancer cell proliferation in vitro. *Cancer Res* 2013;73(24 Suppl): Abstract nr P5-05-07.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA